Sivia Capital Partners LLC Raises Position in Illumina, Inc. $ILMN

Sivia Capital Partners LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 40.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,714 shares of the life sciences company’s stock after purchasing an additional 3,081 shares during the quarter. Sivia Capital Partners LLC’s holdings in Illumina were worth $1,405,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Elyxium Wealth LLC purchased a new stake in shares of Illumina in the fourth quarter worth approximately $25,000. Board of the Pension Protection Fund bought a new position in shares of Illumina in the fourth quarter valued at approximately $26,000. Creative Capital Management Investments LLC grew its holdings in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. bought a new position in shares of Illumina in the fourth quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in shares of Illumina in the fourth quarter valued at approximately $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $98,400.00. Following the completion of the transaction, the insider directly owned 21,568 shares of the company’s stock, valued at approximately $3,450,880. This represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,002,371 shares of company stock valued at $155,472,900 in the last three months. 2.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen lowered Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada assumed coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price for the company. Citigroup upped their target price on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $135.00 target price on shares of Illumina in a report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $138.38.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $170.93 on Thursday. The stock has a fifty day simple moving average of $136.19 and a two-hundred day simple moving average of $133.03. Illumina, Inc. has a 1-year low of $81.75 and a 1-year high of $172.49. The firm has a market cap of $25.86 billion, a price-to-earnings ratio of 31.08, a price-to-earnings-growth ratio of 2.69 and a beta of 1.50. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the company earned $0.97 earnings per share. Illumina’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.